Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Insecticide-treated mosquito nets reduce number of miscarriages by one third in Africa

The results of new research will arm African doctors and researchers with the facts they need to persuade pregnant women to protect their unborn children by sleeping under insecticide-treated mosquito nets (ITNs).

4 Apr 2007

FDA approves Soliris (eculizumab), first treatment for paroxysmal nocturnal hemoglobinuria

The U.S. Food and Drug Administration (FDA) has approved Soliris (eculizumab), the first product for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare type of blood disorder that can lead to disability and premature death.

19 Mar 2007

FDA strengthens safety information for Erythropoiesis-Stimulating Agents (ESAs)

The U.S. Food and Drug Administration (FDA) has issued a public health advisory outlining new safety information, including revised product labeling about erythropoiesis-stimulating agents (ESAs), widely-used drugs for the treatment of anemia.

11 Mar 2007

FDA needs authority to approve generic biologics

AARP called on Congress today to give the Food and Drug Administration (FDA) the authority to approve safe, cost-effective generic versions of often expensive biologic drug therapies.

8 Mar 2007

Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma

The addition of immunotherapy to chemotherapy for malignant skin cancer that has spread does not improve survival rates, researchers have found, and patients have more serious side effects, such as anemia, when the two treatments are combined.

1 Mar 2007

Legislation introduced that would give FDA authority to approve generic versions of biotechnology drugs

Lawmakers in the House and Senate on Wednesday introduced a bill that would allow FDA to approve generic versions of biotechnology medications, USA Today reports.

19 Feb 2007

Mechanism driving iron overload in thalassemia identified

Led by researchers at Weill Cornell Medical College in New York City, an international group of scientists has pinpointed a specific genetic relationship as the cause of dangerous iron overload in persons with a form of the inherited blood disease, beta-thalassemia.

14 Feb 2007

PALB2 gene mutation elevates risk of breast cancer four-fold

Cancer is a complex and common disease caused by a combination of both genetic and environmental factors. An inherited predisposition seems to be involved in at least 5-10 per cent of all cases of breast cancer.

11 Feb 2007

Folate and vitamin B12 preserve cognitive function among seniors

Folate and vitamin B12, two important nutrients for the development of healthy nerves and blood cells, may work together to protect cognitive function among seniors, reports a new epidemiological study from the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University (USDA HNRCA).

11 Feb 2007

New diagnostic technology for routine prenatal genetic testing

Research studies demonstrating the viability of an approach to routinely detect the presence of fetal DNA in a mother's blood to accurately diagnose or rule out genetic defects -- as early as the first trimester -- was presented today at the 27th Annual Meeting of the Society for Maternal-Fetal Medicine being held in San Francisco.

11 Feb 2007

Virtual human metabolic network for medical science

Bioengineering researchers at UC San Diego have painstakingly assembled a virtual human metabolic network that will give researchers a new way to hunt for better treatments for hundreds of human metabolic disorders, from diabetes to high levels of cholesterol in the blood.

30 Jan 2007

Gene produces springy protein keeping nerve cells flexible

If you bend a knee or an elbow, the nerves in your limbs stretch but do not break. A University of Utah study suggests why: A gene produces a springy protein that keeps nerve cells flexible. When the gene was disabled in tiny nematode worms, their nerve cells literally broke.

29 Jan 2007

Sequenom and Lenetix to develop Rhesus D prenatal diagnostic

Sequenom, Inc. and Lenetix Medical Screening Laboratory, Inc., a provider of rapid genetic screening and diagnostic testing for clinicians worldwide, today announced that they have entered into a collaboration and license agreement to develop and commercialize a proprietary non-invasive prenatal Rhesus D (RhD) incompatibility test based on Sequenom patent rights and RT PCR methodology.

29 Jan 2007

WHO unveils new strategy to fight some of the most neglected tropical diseases

The World Health Organization (WHO) and a group of more than 25 partner organizations unveiled a new strategy to fight some of the most neglected tropical diseases that destroy the lives and health of poor people.

26 Oct 2006

Use of subcutaneous injections of Epogen for dialysis patients could save Medicare $537 million annually

Administering the anti-anemia drug Epogen to kidney dialysis patients by subcutaneous injections rather than intravenously could save the federal government hundreds of millions of dollars annually, the Boston Globe reports.

24 Oct 2006

HRSA to allocate $14M to public umbilical cord blood banks

HHS' Health Resources and Services Administration plans to allocate $14 million to public umbilical cord blood banks nationwide in an effort to increase the supply of cord blood from 50,000 to 150,000 units, the AP/Washington Post reports.

17 Oct 2006

FDA approves Zolinza for the treatment of cutaneous T-cell lymphoma

The U.S. Food and Drug Administration (FDA) has approved Zolinza (vorinostat) capsules for the treatment of cutaneous T-cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines.

8 Oct 2006